Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) EBT Margin (2016 - 2021)

Historic EBT Margin for Neurocrine Biosciences (NBIX) over the last 11 years, with Q3 2021 value amounting to 10.3%.

  • Neurocrine Biosciences' EBT Margin rose 323900.0% to 10.3% in Q3 2021 from the same period last year, while for Sep 2021 it was 5.43%, marking a year-over-year decrease of 45100.0%. This contributed to the annual value of 5.91% for FY2019, which is 10600.0% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported EBT Margin of 10.3% as of Q3 2021, which was up 323900.0% from 19.9% recorded in Q2 2021.
  • Neurocrine Biosciences' 5-year EBT Margin high stood at 33.45% for Q3 2018, and its period low was 960.76% during Q2 2017.
  • Moreover, its 5-year median value for EBT Margin was 11.5% (2021), whereas its average is 54.65%.
  • Per our database at Business Quant, Neurocrine Biosciences' EBT Margin skyrocketed by 9546600bps in 2018 and then crashed by -483800bps in 2020.
  • Over the past 5 years, Neurocrine Biosciences' EBT Margin (Quarter) stood at 7.29% in 2017, then skyrocketed by 96bps to 14.3% in 2018, then grew by 11bps to 15.83% in 2019, then plummeted by -240bps to 22.09% in 2020, then skyrocketed by 147bps to 10.3% in 2021.
  • Its EBT Margin stands at 10.3% for Q3 2021, versus 19.9% for Q2 2021 and 11.5% for Q1 2021.